This study was designed to assess the cost-effectiveness of erlotinib compared with
docetaxel in the second-line management of advanced non-small-cell lung cancer (NSCLC) …

Introduction: Erlotinib was recently approved in British Columbia (BC) as a second-line
treatment for advanced NSCLC. A cost-effectiveness analysis was conducted which …

Erlotinib (Tarceva®), an oral epidermal growth factor receptor tyrosine kinase inhibitor, is
associated with modest improvements in survival in patients with advanced non-small cell …

BACKGROUND: Various drug therapies are available for treatment of refractory stage IIIB/IV
non-small cell lung cancer (NSCLC), but their comparative economic value is unclear …

Aim Evaluate costs and benefits of erlotinib as 2nd or 3 rd line treatment of advanced or
metastatic nonsmall cell lung cancer (NSCLC) versus docetaxel, pemetrexed and best …

Background: Lung cancer is the leading cause of cancer deaths worldwide (1.38 million
cancer deaths, 18.2% of the total) and of cancer morbidity (1.61 million new cases, 12.7% of …

Erlotinib has been approved as a third-line treatment for advanced non-small-cell lung
cancer (NSCLC) in British Columbia (BC). A cost-effectiveness analysis was conducted to …

Objective To review and assess the quality of the available evidence on the cost-
effectiveness of erlotinib in the first-line treatment of advanced non-small cell lung cancer …

Background Platinum-doublet, first-line treatment of locally advanced or metastatic non-
small cell lung cancer (NSCLC) is limited to 4–6 cycles. An alternative strategy used to …

Objectives Erlotinib, the first generation of epidermoid growth factor receptor-tyrosine kinase
inhibitor (EGFR-TKI), has been recommended as an essential treatment in patients with non …